ABS-VIR-001

N/A

Report date: 2022/04/02 13:20:12

Base Information

Drug NameABS-VIR-001
Drug Alias NameABS-VIR-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChina Resources Biopharmaceutical Co LtdAb Studio Inc
China Registration ClassN/A

Develop Information

Active CompaniesChina Resources Pharmaceutical Group LtdAb Studio IncChina Resources Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A